HDAC9 and Huntington disease: Supporting this view, administration of histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) consistently shows therapeutic potential in HD models [20]–[28], at least partly through increasing the association of acetylated histones with down-regulated genes and correcting mRNA abnormalities [29].